雷霆vp加速器官网-雷霆vqn加速破解版-雷霆加速加速器官方正版-雷霆vp加速器官网

There is a pressing unmet need for more effective treatments of Pulmonary Arterial Hypertension. A progressive disease caused by cell proliferation in lung blood vessels, PAH (high blood pressure in lung arteries) can adversely affect the heart.
More

雷霆vp加速器官网-雷霆vqn加速破解版-雷霆加速加速器官方正版-雷霆vp加速器官网

We have developed a new class of inhalable drugs to decrease cell proliferation, instead of merely “relaxing” pulmonary arteries as today’s vasodilators do. Our hope after clinical trials is to prove greater efficacy with fewer side effects.
More

雷霆vp加速器官网-雷霆vqn加速破解版-雷霆加速加速器官方正版-雷霆vp加速器官网

In solving the unique problems of our own pulmonary drug research, Pulmokine has developed patented inhalation systems and preclinical efficacy solutions that we are making available to the pulmonary drug development community.
酸酸乳节点网站